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require a positively charged amino acid near the 220/276 region of
the active site (10, 11, 15, 22, 26); an absolute conservation of a
positively charged residue in this region of the active site is re-
quired (15). This positive charge is predicted to be necessary for
the substrate specificity of each -lactamase as well as the evolu-
tionary potential of the -lactamase to expand its hydrolytic pro-
file based on single amino acid substitutions (15). As a result of
comparative analyses of other important class A enzymes, we
explored whether R220 is necessary for the binding and turn-
over of -lactams and -lactamase inhibitors by KPC-2. Based
upon a knowledge of the crystal structure of KPC-2, we hy-
pothesized that the high partition ratio (kcat/kinact) of KPC-2
with respect to clavulanic acid likely correlated with the ab-
sence of a key water molecule, which is anchored by R220 and
E276, and is necessary for the inactivation of KPC-2 by clavu-
lanic acid. By substituting other amino acids for R220 and
E276, we found alterations in the kinetics of inactivation.
To further examine the roles of R220 and E276 in KPC-2, we
also tested the impact of single amino acid substitutions at posi-
tion 220 and 276 on the susceptibility of KPC-2-producing bacte-
ria to -lactams and -lactamase inhibitors. We show here that
R220 is “equivalent” to the R244 found in other class A -lacta-
mases (i.e., TEM-1 and SHV-1). Moreover, a positive charge at
residue 220 is not required for the overall -lactamase activity of
KPC-2; many variants at 220 are “catalytically active” against
tested substrates, except cefotaxime. Interestingly, residue 220
plays a critical role and impacts -lactamase-inhibitor kinetics. In
effect, we uncovered two “contrasting” -lactamases, the R220K
and R220M variants. The R220K variant is the first relatively
“inhibitor-susceptible” variant of KPC-2 that maintains activ-
ity against -lactams. On the other hand, the R220M variant
demonstrates substantially increased Km values for clavulanic
acid, sulbactam, and tazobactam. Moreover, the positioning of
276 is also important to inhibitor kinetics. Finally, we propose
that the location of water molecules in the active site of KPC-2
must be critical for inhibitor resistance and susceptibility. The
synthesis of these findings is a “first step” toward intelligent
-lactamase-inhibitor design for this emerging threat to our
-lactam arsenal.
MATERIALS AND METHODS
Bacterial strains, plasmids, andmutagenesis. K. pneumoniae possessing
blaKPC-2 and Escherichia coli with the pBR322-catI-blaKPC-2 plasmid and
the cloning of blaKPC-2 from pBR322-catI-blaKPC-2 into pBC SK ()
phagemid (Stratagene, La Jolla, CA) and into pET24a() plasmid (No-
vagen, Darmstadt, Germany) were previously described (16, 17). The K.
pneumoniae strain is the parent strain from which blaKPC-2 was identified
and cloned (25). E. coliwith pBR322-catI-blaKPC-2 is the original subclone
of blaKPC-2 (25); E. coli with pBR322-catI-blaKPC-2 is predominantly used
for carbapenemMICs, as it has been shown to express increased amounts
of soluble KPC-2 -lactamase compared to E. coli with pBC
SK()blaKPC-2 (18). E. coliwith pBC SK()blaKPC-2 was subcloned from
pBR322-catI-blaKPC-2 (16). R220 and E276 variants were expressed from
pBC SK()blaKPC-2 and/or pBR322-catI-blaKPC-2 carrying the R220 and
E276 substitutions in E. coli DH10B cells (Invitrogen, Carlsbad, CA). A
Quikchange XL site-directed mutagenesis kit (Agilent) was used to
perform site saturation and site-directed mutagenesis using the man-
ufacturer’s protocol as previously described (17, 18).
Antibiotic susceptibility. Lysogeny broth (LB) agar dilution MICs,
chosen according to the recommendations of the Clinical and Laboratory
Standards Institute (5), were used to phenotypically characterizeK. pneu-
moniae expressing blaKPC-2, E. coli DH10B, and E. coli DH10B with
blaKPC-2 and the blaKPC-2 R220 and E276 variants, as previously described
(16). The chemical structures of the compounds tested are presented in
Fig. 1.
-Lactamase purification. The KPC-2 -lactamase and the R220H,
-K, -A, and -M and E276A and -D variants were purified from E. coli
Origami 2 DE3 cells (Novagen) carrying wild-type (WT) or substituted
pET24a()-blaKPC-2, respectively. Cells were grown in super-optimal
broth (SOB) to an optical density (OD) at 600 nm of 0.6, 0.1 mM isopro-
pyl -D-1-thiogalactopyranoside (IPTG) was added for induction, and
the cells were grown for an additional 3 h. All cells were pelleted and
frozen for 18 h at20°C. Pellets were resuspended in 50 mM Tris-chlo-
ride (Tris-Cl) at pH 7.4 with 1 mMmagnesium sulfate. Pellets were lysed
with lysozyme (Sigma) (40 mg/liter), and benzonase nuclease (Novagen)
(1.0 U/ml) was added to digest nucleic acids, as some cells may burst
during the extraction. EDTA (2.0 mM) was added to complete the
periplasmic fractionation. The lysed cells were centrifuged at 12,000 rpm
for 10 min to remove the cellular debris. The supernatant (e.g., crude
extract) was further enriched for -lactamase by the use of preparative
isoelectric focusing (pIEF). A Sephadex G100 gel matrix and commer-
cially prepared ampholines (Amersham Biosciences) (pH 3.5 to 10.0)
were used in the pIEF gel. The pIEF gel was run overnight at 4°C at a
constant power of 8W on aMultiphor II isoelectric focusing apparatus
(Amersham Pharmacia Biotech). After the pIEF gel was run overnight,
areas of the gel demonstrating -lactamase activity by nitrocefin
(NCF) overlay were cut from the gel, eluted with 20 mM phosphate-
buffered saline (PBS) (pH 7.4) on polyethylene glycol columns (Am-
ersham Biosciences), and concentrated using an Amicon Ultra-4 con-
centrator (molecular weight [MW] cutoff of 10,000; Millipore). A
HiTrap Q HP column (GE Healthcare Life Sciences) was used to per-
form fast protein liquid chromatography on an A¨kta P-900 system (GE
Healthcare Life Sciences). Proteins were eluted using a salt gradient (0
to 15%) and a mixture of 50 mM Tris-Cl at pH 8.8 and 50 mM Tris-Cl
at pH 8.8 with 1.0 M sodium chloride. The purity of the fractions was
determined by sodium dodecyl sulfate polyacrylamide gel electropho-
resis. Gels were stained with Coomassie brilliant blue R250. Protein
concentrations were determined by measuring absorbance at   280
nm and using the protein’s extinction coefficient (ε; 39,545 M1
cm1 at 280 nm); the values were obtained using the ProtParam tool at
http://us.expasy.org/tools.
Immunoblotting. E. coli strains expressing blaKPC-2 and all variants
were grown in LB exponentially to an OD at 600 nm of between 0.7 and
0.8. Cells were pelleted and lysed to prepare crude extracts as described
above. Positions 220 and 276 do not lie within the 3 major epitopes of
the KPC-2 antibody, and immunoblotting was completed as previ-
ously described (17). Membranes were probed with a polyclonal anti-
KPC-2 antibody (Sigma) and a loading control polyclonal anti-DNAK
antibody (Stressgene). For detection, protein G-horseradish peroxi-
dase (protein G-HRP) conjugate (Bio-Rad) and anti-mouse second-
ary-HRP conjugate antibody were used. Blots were developed using an
ECL-Plus developing kit (GE Healthcare Life Sciences) according to
the manufacturer’s instructions. A Fotodyne Luminary/FX worksta-
tion was used to capture images.
Kinetics. Steady-state kinetic parameters were determined using an
Agilent 8453 diode array spectrophotometer (Santa Clara, CA) as previ-
ously described (16, 18). Briefly, each assay was completed using 10 mM
PBS at pH 7.4 at room temperature (25°C) with the ratio of the concen-
tration of the enzyme (E) to that of the substrate (S) chosen to establish
pseudo-first-order kinetics. To measure hydrolysis rates, we used the fol-
lowing extinction coefficients (ε): nitrocefin (NCF) ε, 17,400 M1
cm1 at 482 nm; ampicillin ε,900 M1 cm1 at 235 nm; piperacillin
ε,820M1 cm1 at 235 nm; cefotaximeε,7,250M1 cm1 at 262
nm; imipenem ε,9,000M1 cm1 at 299 nm, and clavulanic acid ε,
1,630 M1 cm1 at 235 nm. Using Enzfitter (Biosoft Corporation, Fer-
guson, MO), a nonlinear least-square fit of the data (Henri Michaelis-
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drolysis of 100 MNCF. The I:E ratio necessary to inhibit the initial rate of
hydrolysis of NCF by greater than 90% compared to the control (enzyme
without inhibitor) was determined.
To measure overall activity of KPC-2 and the R220K and -M variants
upon incubation with clavulanic acid, progress curves were taken at a
fixed concentration of enzyme (10 nM), 50 M NCF, and increasing
concentrations of clavulanic acid (400 to 3,200 M).
ESI-MS. Electrospray ionization mass spectrometry (ESI-MS) of the
intact KPC-2 and R220K variant -lactamases was performed using an
Applied Biosystems (Foster City, CA) QStar Elite quadrupole-time-of-
flight mass spectrometer equipped with a TurboIon spray source. -Lac-
tamases were incubatedwith clavulanic acid for 1, 2.5, 5, 10, and 20min at
room temperature in 10 mM PBS (pH 7.4). The ratio of inhibitor to
-lactamase (I:E) was 100:1 for all reactions. Then, reactions were termi-
nated by addition of 0.2% formic acid. All samples were desalted and
concentrated using a C18 ZipTip (Millipore, Billerica, MA) pipette tip
according to the manufacturer’s protocol. Eluted protein samples were
diluted with 50% acetonitrile and 0.2% formic acid to a concentration of
10 mM and infused at a rate of 0.5l per min, and data were collected for
2 min. Spectra were deconvoluted using the Applied Biosystems Analyst
program.
Molecular modeling. The crystal coordinates of KPC-2 (Protein Data
Bank [PDB] accession code 2OV5 [13]) were used to construct represen-
tations of the R220A, R220M, R220K, E276D, and E276A variants of
KPC-2, as well as to represent the Michaelis complexes of clavulanic acid,
with the KPC-2 -lactamase and the R220K variant by the use of Discov-
ery Studio 2.5 (DS 2.5; Accelrys, Inc., SanDiego, CA)molecularmodeling
software as previously described (18). The R220A, R220M, R220K,
E276D, and E276A variants were designed by substitution of the residues
at positions 220 and 276, respectively. Clavulanic acid was constructed
using Fragment Builder tools and was minimized using a Standard Dy-
namics Cascade protocol of DS 2.5. The unhydrolyzed clavulanic acid was
automatically docked into the active site of KPC-2 -lactamase by the use
of the Flexible Docking module of DS 2.5. The protocol allowed place-
ment of a “flexible” -lactamase inhibitor in the “flexible” active site of
KPC-2. After docking, the most favorable pose of clavulanic acid was
chosen (demonstrating a short distance [2 to 3Å] between Ser70:O andC7
of clavulanic acid as well as anticipated active site contacts) and the com-
plex was created. The Michaelis complex of the R220K variant with
clavulanic acid was created in a similar fashion. To check the stability and
look for possible conformational changes of the complex, Molecular Dy-
namics Simulation (MDS) was conducted on apo-KPC-2, KPC-2–clavu-
lanic acid, and the R220K:clavulanic acid complexes, as previously de-
scribed (18).
RESULTS
Susceptibility testing of R220 and E276 variants. To assess the
impact of amino acid substitutions at positions 220 and 276 on the
TABLE 1 MICs of -lactamsa
Strain
MIC (mg/liter)
AMP PIP THIN TAZ TAX IMIb ERTAb MEROb DORIb
K. pneumoniae 8,192 1,024 1,024 32 16 8 8 4 4
E. coli DH10B pBR322-catI-blaKPC-2 4,096 1,024 512 32 8 4 2 2 2
E. coli DH10B pBC SK() blaKPC-2 256 128 256 2 2 0.5 0.25 0.25 0.25
R220A 512 32 32 0.5 0.125 1 0.06 0.125 0.06
R220G 512 16 32 0.5 0.06 0.5 0.06 0.06 0.125
R220I 32 2 4 0.5 0.06 0.25 0.06 0.06 0.06
R220L 512 32 64 0.5 0.06 1 0.06 0.06 0.125
R220M 1,024 32 32 0.5 0.06 2 0.125 0.125 0.125
R220V 256 16 32 0.5 0.25 1 0.06 0.06 0.06
R220F 512 32 16 0.25 0.125 2 0.06 0.06 0.125
R220W 256 4 8 0.25 0.125 0.5 0.06 0.06 0.125
R220Y 512 32 16 0.5 0.06 1 0.06 0.06 0.125
R220C 128 8 16 0.25 0.125 0.5 0.06 0.06 0.06
R220N 64 4 8 0.25 0.06 0.5 0.06 0.06 0.06
R220P 64 4 4 0.25 0.06 N/Ac N/A N/A N/A
R220Q 512 32 64 0.5 0.125 2 0.125 0.125 0.25
R220S 512 32 64 0.5 0.125 2 0.125 0.06 0.125
R220T 256 16 32 0.5 0.125 1 0.06 0.06 0.125
R220D 64 4 16 0.25 0.06 0.5 0.06 0.06 0.06
R220E 512 32 64 0.5 0.125 2 0.125 0.06 0.125
R220H 1,024 64 128 1.0 0.125 2 0.25 0.125 0.25
R220K 256 16 64 0.5 0.25 2 0.5 0.5 0.5
E276Ad 512 64 128 N/De 2 0.25 0.25 0.25 0.125
E276Dd 2,048 256 512 N/D 4 0.5 0.25 0.5 0.5
E276Nd 512 128 128 N/D 2 1 0.25 0.125 0.25
E276Rd 32 4 16 N/D 0.25 0.25 0.06 0.06 0.06
E. coli DH10B 1 2 4 0.25 0.06 0.25 0.06 0.06 0.06
E. coli DH10B pBC SK () 1 2 4 0.25 0.06 0.25 0.06 0.06 0.06
a The K. pneumoniae strain is the primary strain from which blaKPC-2 was first identified and cloned (25). E. coli with pBR322-catI-blaKPC-2 is the original subclone of blaKPC-2 and
has been shown to express increased amounts of KPC-2 relative to E. coli with pBC SK()blaKPC-2. -Lactam abbreviations: ampicillin, AMP; piperacillin, PIP; cephalothin, THIN;
cefotazidime, TAZ; cefotaxime, TAX; imipenem, IMI; ertapenem, ERTA; meropenem, MERO; doripenem, DORI. The data shown are from four independent determinations.
b E. coli with pBR322-catI-blaKPC-2 is predominantly used for determination of carbapenemMICs (as indicated by shading) (18, 25).
c N/A, variant R220P was not obtained during the initial screen for mutants.
d All E276 variants were expressed from pBC SK () blaKPC-2 in E. coli DH10B.
e N/D, values were not determined.
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KPC-2 -lactamase in bacteria, we tested the susceptibility profile
of E. coli containing variants of KPC-2. Our analysis shows that
variants at R220 demonstrated decreased MICs for all tested
-lactams, with the exception of ampicillin, in comparison to the
WTenzyme expressed inE. coliDH10B (Table 1).Only theR220H
variant expressed in E. coliDH10B exhibited MICs nearest to WT
levels.
Increased ampicillin-clavulanic acidMICswere detected for 12
of the 19 variant strains (i.e., R220A, -G, -L, -M, -F, -W, -Y, -Q, -S,
-T, -E, and -H; Table 2). In stark contrast, none of the 19 variant
strains demonstrated increased sulbactam or tazobactam MICs.
The R220M variant displayedMICs closest to the KPC-2 levels for
all the tested-lactam–-lactamase-inhibitor combinations. Sur-
prising, the R220K variant exhibited significantly decreasedMICs
for the -lactam–-lactamase-inhibitor combinations in com-
parison to KPC-2. Other variants (R220D, -I, -N, and -P) also
demonstrated decreased MICs for -lactam–-lactamase-inhibi-
tor combinations, but unlike the R220K variant, they were also
more susceptible to the partner -lactam. Replacing E276 with
uncharged amino acids, such as alanine or asparagine, -lactam
and -lactam–-lactamase-inhibitor resistance was maintained
(Tables 1 and 2).
Immunoblotting of the R220 and E276 variants reveals only
slightdifferences inproteinexpressionamongthevariants. Immu-
noblottingusing apolyclonal anti-KPC-2 antibody revealedminimal
changes in expression among the variants (see Fig. S1 in the supple-
mentalmaterial).Wenote that theR220I, -K, and -Pmutants didnot
express as well as KPC-2.
Kinetic analysis of selected variants ofKPC-2 indicates that a
positive charge at position 220 is not an absolute requirement
for hydrolysis of -lactams, with the exception of cefotaxime.
KPC-2 and the R220K, -H, -M, and -A and E276A and -D variants
were purified to95% homogeneity. Steady-state kinetics analy-
ses were performed using piperacillin, cephalothin, NCF, cefo-
taxime, and imipenem (Table 3).









K. pneumoniae 32 512 512/64




R220A 16 32 32/4
R220G 8 32 16/2
R220I 1 1 4/0.5
R220L 8 32 32/4
R220M 8 64 64/8
R220V 2 16 16/2
R220F 16 32 32/4
R220W 8 16 16/2
R220Y 16 32 32/4
R220C 8 16 16/2
R220N 2 8 8/1
R220P 2 8 4/0.5
R220Q 16 32 32/4
R220S 16 32 32/4
R220T 8 32 32/4
R220D 1 4 8/1
R220E 8 32 32/4
R220H 8 32 32/4
R220K 1 8 8/1
E276A 8 32 64/8
E276D 32 256 256/32
E276N 8 64 128/16
E276R 1 1 4/0.5
DH10B 1 1 4/0.5
DH10B pBC SK() 1 1 4/0.5
a Ampicillin (AMP) was maintained at a constant concentration of 50 mg/liter, and
clavulanic acid and sulbactam concentrations ranged from 1 mg/liter to 32 mg/liter and
1 mg/liter to 512 mg/liter, respectively. Piperacillin (PIP)/tazobactam ratios ranged 8:1
from 1/0.125 mg/liter to 512/64 mg/liter. The data shown are from a single experiment
representative of four independent experiments.
b All variants were expressed from pBC SK () blaKPC-2 in E. coli DH10B; see Table 1
footnote for additional information on strains.












Piperacillin WT 12 1 65 7 5.4 0.5
R220H 13 1 68 7 5.2 0.5
R220A 164 16 193 20 1.2 0.1
R220M 35 4 85 9 2.4 0.2
R220K 23 2 40 4 1.7 0.2
E276A 12 1 59 6 4.8 0.5
E276D 5.2 0.5 38 4 7.2 0.7
Cephalothin WT 38 4 223 20 5.9 0.6
R220H 108 11 206 20 1.9 0.2
R220A 207 21 379 38 1.8 0.2
R220M 98 10 156 16 1.6 0.2
R220K 45 5 88 9 2.0 0.2
E276A 24 2 157 16 6.5 0.6
E276D 12 1 139 14 11 1
Nitrocefin WT 8 1 130 13 16 2
R220H 16 2 260 26 16 2
R220A 54 5 327 33 6.1 0.6
R220M 94 9 724 72 7.7 0.8
R220K 10 1 120 12 12 1
E276A 4.9 0.4 97 10 19 2
E276D 4.1 0.4 77 8 19 2
Cefotaxime WT 190 19 140 14 0.7 0.1
R220H N/Da N/D N/D
R220A N/D N/D N/D
R220M N/D N/D N/D
R220K N/D N/D N/D
E276A 278 28 118 12 0.4 0.1
E276D 253 25 100 10 0.5 0.1
Imipenem WT 21 2 21 2 1.0 0.1
R220H 11 1 9 1 0.8 0.1
R220A 18 2 4 1 0.2 0.1
R220M 28 3 10 1 0.4 0.1
R220K 5 1 7 1 1.4 0.1
E276A 12 1 11 1 0.9 0.1
E276D 10 1 13 1 1.3 0.1
a N/D, values could not be determined; variants did not hydrolyze cefotaxime at
detectable levels. In addition, attempts to obtain a Ki for cefotaxime were not successful
even when using excess (up to 10 mM) cefotaxime, revealing that binding of cefotaxime
was also compromised in these variants.
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For the variants tested against the penicillins, cephalosporins,
and carbapenems studied, there was an overall decrease in cata-
lytic efficiency (kcat/Km reduced by 50% or greater). For piperacil-
lin, nitrocefin, and imipenem, the R220H variant behaved simi-
larly to the WT enzyme. The R220K variant displayed decreased
kcat/Km values (i.e., 3.2-fold) for most substrates. Interestingly,
the Km value for imipenem for the R220K variant decreased from
21  2 M for KPC-2 to 5  1 M for the R220K variant, but
overall, the kcat/Km ratio remained the same.
Measuring the kinetics for the R220M variant against various
substrates revealed some decreases (i.e.,3.7-fold) in overall cat-
alytic efficiency, mostly the result of increased Km values for sub-
strates (Table 3). The R220A variant showed significantly in-
creased Km values for piperacillin, cephalothin, and NCF from
5.4-fold to upwards of 13.7-fold. In contrast, slight increases in the
kcat value of 3-fold were also detected. Cefotaxime hydrolysis
was notmeasurablewith anyR220 variant and thus appeared to be
the process most affected by loss of arginine at position 220. The
kinetic analysis of the E276A and -D variants revealed kinetic pa-
rameters similar to those of KPC-2 (Tables 3 and 4).
R220K cannot hydrolyze clavulanic acid, while R220M dem-
onstrates increasedKm values for all-lactamase inhibitors. In-
hibition/inactivation by clavulanic acid is a complex multistep
process involving the formation ofmany intermediates (Fig. 2) (3,
6). To further dissect the differences between KPC-2 and the
R220K and -M variants, we performed detailed kinetics.
The Km values for the purified R220K -lactamase were lower
than those seen with KPC-2; however, the partition ratios (kcat/
kinact) after 15 min for all inhibitors were significantly decreased
(i.e., up to a 36-fold decrease for clavulanic acid) (Table 4).
Assessing the activity of the R220K variant, we found that with
400Mclavulanic acid, the R220K variant wasmostly inactivated
(Fig. 3C), while at 3.2 mM clavulanic acid, KPC-2 still retained
-lactamase activity (Fig. 3A). Measuring hydrolysis of clavulanic
acid revealed that KPC-2 had a kcat value of 18 2 s
1 for clavu-
lanic acid, while the R220K variant’s levels of clavulanic acid hy-
drolysis were undetectable (Table 4 and Fig. 4).
The R220M variant displayed a nearly 20-fold increase in Km
values for clavulanic acid and sulbactam and partition ratios of
30,000 and	100,000, respectively (Table 4). The Km value of the
R220M variant for tazobactam also increased from 66 M to 257
M, with a minor reduction (i.e., 2-fold) in the partition ratio.
The overall activity of the R220M variant measured with time in
the presence of increasing concentrations of clavulanic acid re-
vealed that it was more susceptible to inactivation than KPC-2
(Fig. 3A and B). Like those of the R220K variant, the R220M vari-







Km (M) WT 25 3 184 18 66 7
R220M 485 49 3,600 400 257 26
R220K 14 1 146 15 36 4
E276A 15 1 219 22 82 8
E276D 11 1 319 32 192 20
kcat (s
1) WT 18 2 N/Ab N/A
kcat/kinact (15 min) WT 9,000 3,000 500
R220M 30,000 	100,000 250
R220K 250 250 25
E276A 4,500 1,000 250
E276D 9,000 2,000 500
a NCF at 100 Mwas used as the substrate.
b N/A, values were not determined.
FIG 3 Activity curves of the kinetic interactions of clavulanic acid with KPC-2 and the R220M and -K variants. The reaction of 10 nMKPC-2 (A) or the R220M
(B) or -K (C) variant with increasing concentrations of clavulanic acid over time wasmonitored at an absorbance of 482 nm using 50Mnitrocefin as a reporter
substrate for -lactamase activity. Compared to KPC-2 and the R220M variant, the R220K variant is readily inactivated by clavulanic acid.
FIG4 Monitoring hydrolysis using clavulanic acidwithKPC-2 and theR220K
and -M variants. Clavulanic acid was incubated with KPC-2 or the R220M or
-K variant, and hydrolysis at 235 nm was monitored over time.
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ant’s levels of hydrolysis of clavulanic acid were also undetectable
(Table 4 and Fig. 4).
Mass spectrometry reveals adducts with the R220K variant
but not KPC-2.To further discern the nature of the intermediates
of inactivation by clavulanic acid in the reaction pathway of
KPC-2 and the R220K variant, we performed electrospray ioniza-
tionmass spectrometry (ESI-MS). Timedmass spectrometry data
showed that R220K reacts with clavulanic acid to form various
inactivation products (52,70, and88) (Fig. 5) (3, 6). These
inactivation products formed within 1 min and increased in in-
tensity during a 10-min time course; free -lactamase reappeared
by 20 min. Adducts were not observed with KPC-2 even at high
ratios of inhibitor to enzyme (data not shown).
Modeling of KPC-2 and the R220K variant in apo-enzyme
and complexed forms.To gain insight into the structural changes
that might have been occurring, we performed molecular model-
ing and MDS. Modeling of the KPC-2 and R220A, -M, and -K
apo-enzymes predicted a significant 3.5-Å shift of the E276 side
chain in toward the active site in the R220K variant (Fig. 6A). All
other movements of active-site residues (S70, K73, W105, N132,
E166,N170, T216,K234, T235, T237, andH274)were less than 1.7
Å. The overall topologies of the active sites of the two proteins
were different; the active site of the R220K variant appeared larger
and more electropositive (Fig. 6B and C).
Unhydrolyzed clavulanic acid was docked into the active sites
of KPC-2 and the R220K variant, and MDS was run. KPC-2 re-
quired 100 ps to reach equilibration with the Michaelis complex
(data not shown). The KPC-2 apo-enzyme took only 10 ps to
reach equilibration (data not shown). The R220K variant reached
equilibration rapidly, i.e., within 5 ps, with theMichaelis complex
(data not shown).
Our simulations indicated that the inhibition of -lactamases
by clavulanic acid was largely dependent on the position of two
key water molecules. One water molecule (Wat1) is critical for
deacylation, while the other water molecule (Wat2) is necessary
for protonation of the clavulanic acid oxonium intermediate, thus
driving inhibition/inactivation. In the KPC-2–clavulanic acid
complex, Wat1 was clearly anchored via hydrogen bonds to E166,
a residue shown to be essential for deacylation (Fig. 6B). Wat2
formed interactions with E276 but not with clavulanic acid. In the
R220K–clavulanic acid model, the movement of E276 resulted in
the displacement ofWat1 away from E166 inmost conformations
(Fig. 6C). In addition,Wat2made hydrogen bonds with E276 and
clavulanic acid and thus was available to accelerate secondary ring
opening and promote inhibition (Fig. 6C).
Consistentwith ourMIC and kinetic data,molecularmodeling
studies demonstrated that major structural changes in the apo-
enzymes of E276A and -D were not present (data not shown).
DISCUSSION
KPC-2 represents one of the most clinically important serine car-
bapenemases found in Gram-negative bacteria (7, 16, 21, 23, 25).
Our analysis of the amino acid sequence requirements for catalysis
reveals that the positive charge at position 220 modulates the cat-
alytic activity of KPC-2 -lactamase against most substrates; sub-
stitution at position 220 by other amino acids results in active
enzymes that possess a wide range of catalytic efficiencies. This
observation is in sharp contrast to the role of R220 in Streptomyces
albus G -lactamase, where the substitution of R220 by leucine
completely abrogates activity of this enzyme (11). Similar obser-
vations were noted with R244 variants of TEM-1 and SHV-1 (10,
11, 15, 22, 26). Thus, R220 is the “R244” equivalent in KPC-2.
For susceptibility testing with -lactam–-lactamase-inhibi-
tor combinations, 12 of 19 variants displayed increased MICs for
ampicillin-clavulanic acid. However, the variants do not have in-
creased MICs for ampicillin-sulbactam or piperacillin-tazobac-
tam, revealing a critical difference between the inhibition mecha-
nisms of oxapenams versus sulfones. We previously reported the
“clavulanic acid-resistant sulfone-susceptible” phenotype with
T237 andW105 variants of KPC-2 (17, 18). These results led us to
hypothesize that this phenotype was due to differences in the in-
activation chemistry of the sulfones versus clavulanic acid with
KPC-2 (18). Now, we also predict that a critically positionedwater
molecule, Wat2, may additionally be further displaced in the
KPC-2 variants that result in this phenotype (Fig. 6). Without
water present, we postulate that the enolate becomes a poor leav-
ing group and that clavulanic acid is rapidly deacylated in these
variants (higher partition ratios) (Fig. 6 and 7). The sulfones do
not requireWat2 for secondary ring opening and inactivation and
thus are unaffected bymovement ofWat2 in variant-lactamases.
FIG 5 Timed mass spectrometry of the R220K variant with clavulanic acid. In a timed mass spectrometry experiment, clavulanic acid was reacted with the R220K
variant. Sampleswerecollectedat1min,2.5min,5min,10min, and20min.Anenzyme-alonecontrolwasalso run(i.e., theR220Kvariant; 28,1183atomicmassunits
[amu]).Massadductsof513amu(propynyl enzymeorenol ether),693amu(aldehyde), and883amu(hydratedaldehyde)wereobservedwith theR220K
variant.
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Two “different” -lactamases, R220M and R220K, were fur-
ther studied. The R220M variant demonstratesMICs similar to or
higher than WT levels and displays increased Km values for the
commercially available -lactamase inhibitors (clavulanic acid,
sulbactam, and tazobactam). The mechanism of resistance sug-
gests that there is decreased binding affinity (Ki  k1/k1); when
high concentrations of inhibitor (	320,000:1 I:E ratio) were
added, inactivation was measured. This mechanism of resistance
is different from that of WT KPC-2, as the R220M variant has the
ability to confer inhibitor resistance based on hydrolysis as op-
posed to loss of binding.
The MICs for the R220K variant were lower than those seen
with the WT for all tested -lactam–-lactamase combinations.
Interestingly, by substituting the side chain of arginine for lysine,
binding of clavulanate, sulbactam, and tazobactam is improved,
and kcat/kinact becomes much lower. Unlike the results seen with
theWT, hydrolysis of clavulanic acid by the R220K variant cannot
be detected and the variant is readily inactivated by clavulanic acid
over time. Taken together, the combination of these factors pro-
duces a relatively “inhibitor-susceptible” variant of KPC-2.
Molecular modeling studies suggested that the shift of E276
toward the active site drives inhibitor susceptibility in this en-
FIG 6 Molecular modeling of KPC-2 and the R220A, -M, and -K variants. (A) The apo-enzyme of the KPC-2 (gray) was superimposed on the apo-enzymes of
the R220A (orange), -M (dark blue), and -K (cyan) variants, revealing a 3.5-Å shift in E276 for the R220K variant. (B) Electrostatic surface of the active site of
KPC-2–clavulanic acid (left). The molecular representation of KPC-2 (gray) with clavulanic acid (blue) reveals that Wat1 (red) forms hydrogen bonds (green
dashed line) with E166 (top right). The distance (d) in angstroms between E166 and Wat1 throughout the 100-ps simulation (bottom right) is indicated. (C)
Electrostatic surface of the active site of the R220K variant-clavulanic acid (left). Themolecular representation of the interaction of the R220K variant (gray) with
clavulanic acid (blue) indicates that Wat2 (red) is hydrogen bonded (green dashed line) to clavulanic acid and E276 (top right). The distance (d) in angstroms
between C7 of clavulanic acid and Wat2 throughout the 5-ps simulation (bottom right) is indicated.
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FIG 7 Mechanisms of clavulanic acid interactions with KPC-2 and the R220K variant. (A)Mechanism of clavulanic acid resistance byWTKPC-2. Themajor pathway
is illustrated; onlyminor amounts of enaminemay form and thus are not depicted in this scheme. The S70 nucleophile attacks the-lactam ring. The deacylationwater
is positioned close to E166, promoting deacylation of the acyl-enzyme complex. (B)Mechanismof clavulanic acid inhibition of the R220K variant. The S70 nucleophile
attacks the-lactam ring. The protonationwatermolecule is closely anchored by E276 and clavulanic acid, thus promoting secondary ring opening and protonation of
the oxonium ion intermediate to form the imine. The imine ismostly converted to the inactivation products: an enoyl etherwhich decomposes to the propynyl enzyme
and an aldehyde which gets hydrated to generate a hydrated aldehyde. Aminor fractionmay tautomerize to the enamine form; thus, it is not represented.
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zyme through repositioning of two key water molecules (i.e.,
the deacylation water and the protonation water) in the active
site.
In agreement with the contrasting substrate profiles of WT
KPC-2 and the R220K variant, during MDS, KPC-2 required 100
ps to reach equilibration with the Michaelis complex. However,
the R220K variant reached equilibration rapidly (within 5 ps) with
the Michaelis complex, suggesting that it quickly forms a stable
complex with clavulanic acid, thus further supporting the inhibi-
tion of R220K by clavulanic acid.
Our analysis ofWTKPC-2 in comparison to the R220K variant
with respect to clavulanic acid is indicative of two very different
reaction pathways with clavulanic acid (Fig. 7). For WT KPC-2,
the rate constant for deacylation, k3, is much larger than k4, the
rate constant for ring opening and tautomerization, and we
predict that only a very small portion is converted to either
enamine intermediate, as these species as well as other inacti-
vation products are not trapped by mass spectrometry. Thus,
after the S70 nucleophile attacks the -lactam ring forming the
acyl-enzyme, the majority of the acyl-enzyme complex is hy-
drolyzed (Fig. 7A). Our modeling studies suggest that Wat1 is
positioned close to E166, promoting deacylation of the acyl-
enzyme complex rather than protonation of the oxonium ion
intermediate from Wat2.
In the case of the R220K variant, k3, the rate constant for
deacylation is still larger than k4 but is much lower than k3 for
WT KPC-2, as evidenced by a partition ratio for clavulanic acid
that is lower by 36-fold and the lack of hydrolysis of clavulanic
acid. In addition, k6, the rate constant for the formation of the
inactivation products, is larger than k5, the rate constant for
formation of the enamine species; we predict that little of the
enamine intermediate is formed. The rate of the reaction of the
R220K variant with clavulanic acid is slower than that of the
WT, as mass spectrometry revealed that inactivation products
formed in a 20-min timed study.
How does one explain this in a mechanism? The S70 nucleo-
phile attacks the -lactam ring forming the acyl-enzyme, but the
position of E276 stimulates inhibition in the R220K variant due to
the placement of Wat1 andWat2 (Fig. 7B). TheWat2 molecule is
closely anchored by E276, thus promoting secondary ring opening
and protonation of the oxonium ion intermediate to form the
imine. The imine ismostly converted to the inactivation products:
enoyl ether which deacylates to the propynyl enzyme and an
aldehyde which gets hydrated to generate a hydrated aldehyde.
A minor fraction tautomerizes to the trans-enamine form.
Eventually, inactivation products decompose, since mass spec-
trometry showed that, by 20 min, the -lactamase began to
deacylate and the presence of free enzyme was observed.
In summary, we report here for the first time the identifica-
tion of an “inhibitor-susceptible” variant of KPC-2 that main-
tains catalytic activity against -lactams. The predicted shift of
one residue in the active site of KPC-2 makes this notoriously
inhibitor-resistant -lactamase susceptible to clavulanic acid.
Thus, R220 appears to function as a “switch” between inhibitor
resistance and susceptibility in the KPC-2 -lactamase. These
insights allow us to consider the future design of novel inhibi-
tors of this carbapenemase. The challenge for the medicinal
chemist is to alter the R2 side chain of clavulanic acid so that
Wat2 approximates E276 and R220 to promote inactivation,
thus generating a potent inhibitor of the KPC-2 -lactamase.
We also hasten to add that the mechanistic considerations that
apply to sulfone inhibitors may offer an important alternative
to inhibit KPC-2 -lactamases (12).
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